The Inflation Reduction Act (IRA) changes the way Medicare pays for prescription drugs. These changes will impact various stakeholders, including Medicare, Medicare enrollees, drug manufacturers, and others. We present a high-level approach for how to evaluate each IRA Medicare drug-related provision, including identification of key research questions and outcomes; the potential methods that can be used; and the challenges that may arise. We also describe the issues that were considered in the development of the evaluation framework. The framework presented here can be used to develop and implement a comprehensive evaluation of the IRA’s Medicare drug-related provisions.
*This content is in the process of Section 508 review. If you need immediate assistance accessing this content, please submit a request to Bisma Sayed, Bisma.Sayed@hhs.gov. Content will be updated pending the outcome of the Section 508 review.
Related Products:
- Inflation Reduction Act Research Series: Medicare Part D Enrollee Out-of-Pocket Spending: Recent Trends and Projected Impacts of the Inflation Reduction Act
- Inflation Reduction Act Research Series: Understanding Development and Trends in Utilization and Spending for Drugs Selected Under the Medicare Drug Price Negotiation Program
- Inflation Reduction Act Research Series: Medicare Part D Enrollee Savings from Elimination of Vaccine Cost-Sharing